Trials / Completed
CompletedNCT01646203
A Study of IMC-TR1 in Participants With Advanced Solid Tumors
Phase 1 Study of Anti-TGFβRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the safety and tolerability of anti-TGFβRII monoclonal antibody (IMC-TR1) in participants with advanced solid tumors, as well as gather evidence of anti-tumor activity.
Detailed description
This is the first-in-human Phase 1 study of IMC-TR1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IMC-TR1 | Administered intravenously |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2012-07-20
- Last updated
- 2019-01-18
- Results posted
- 2019-01-18
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01646203. Inclusion in this directory is not an endorsement.